Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 31/05/2023, Revision: 01, Status: Authorised

Timetable: Annual reassessment - ATMP

Timetable: Annual renewal application of conditional marketing authorisation - ATMP

Timetable: Marketing authorisation renewal application - ATMP

Marketing authorisation renewal application - ATMP: Initial 90-day assessment

Timetable: Type II variation and worksharing application assessment - ATMP

Timetable: Type IB variation requiring linguistic review

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Muscular Atrophy, Spinal, Date of authorisation: 18/05/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Modigraf, tacrolimus, Graft Rejection, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Lipodystrophy, Familial Partial, Date of authorisation: 29/07/2018, Revision: 9, Status: Authorised